TRUQAP 160 MG — DIN 02544733
CAPIVASERTIB : 160 MG · ASTRAZENECA CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TRUQAP?
TRUQAP 160 MG contains CAPIVASERTIB : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02544733, held by ASTRAZENECA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRUQAP used for?
TRUQAP® (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Capivasertib cost around the world?
Capivasertib is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United Arab Emirates | public | 2 | 2 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Italy | ex-factory (classe H) | 2 | 2 | EUR███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| Saudi Arabia | public | 1 | 2 | SAR███.██ |
16 pack listings across 13 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Capivasertib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Capivasertib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Capivasertib — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASTRAZENECA CANADA INC | 2 | 2 | TRUQAP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 160 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Both strengths of TRUQAP are available in aluminum foil/foil blister in cartons of 64 tablets (4 blister packs of 16 film-coated tablets). |
| Storage | Store at room temperature between 15°C to 30°C in original package. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Capivasertib |
|---|---|
| ATC code | L01EX27 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02544733 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2544733 |
| Brand name | TRUQAP |
| Generic / active ingredient | CAPIVASERTIB : 160 MG |
| Market authorization holder | ASTRAZENECA CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01EX27 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01EX |
| Current status | MARKETED |
| Status date | 16-Apr-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dose of TRUQAP in combination with fulvestrant is 400 mg (two 200 mg tablets) taken orally twice daily, approximately 12 hours apart (total daily dose of 800 mg), for 4 days followed by 3 days off treatment. TRUQAP can be taken with or without food. Treatment with TRUQAP should continue until disease progression or unacceptable toxicity occurs. TRUQAP tablets should be swallowed whole with water and not chewed, crushed, dissolved, or divided. TRUQAP tablets should not be ingested if they are broken, cracked, or otherwise not intact. If a dose of TRUQAP is missed, it can be taken within 4 hours after the time it is usually taken. After more than 4 hours, the dose should be skipped. The next dose of TRUQAP should be taken at the usual time. There should be at least 8 hours between doses. If the patient vomits, a replacement dose should not be taken. The next dose of TRUQAP should be taken at the usual time. Dose modification for Adverse Reactions: First dose reduction: 320 mg twice daily (equivalent to a total daily dose of 640 mg) for 4 days followed by 3 days off treatment (Two 160 mg tablets per dose). Second dose reduction: 200 mg twice daily (equivalent to a total daily dose of 400 mg) for 4 days followed by 3 days off treatment (One 200 mg tablet per dose). A maximum of 2 dosing reductions are recommended after which the patient should be discontinued from treatment with TRUQAP.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
TRUQAP (capivasertib) is contraindicated in patients who are hypersensitive to capivasertib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 Dosage Forms, Strengths, Composition, and Packaging.
Warnings and precautions
Serious Warnings and Precautions: • Cutaneous adverse reactions including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Erythema Multiforme (EM) and Palmar-plantar erythrodysesthesia. • Hyperglycemia, including diabetic ketoacidosis. Some cases have been fatal. • Severe Diarrhea associated with dehydration and acute kidney injury. Driving and Operating Machinery: TRUQAP has no influence on the ability to drive and use machines. However, during treatment with capivasertib, fatigue has been reported. Patients who experience this symptom should be advised to use caution when driving or using machines. Endocrine and Metabolism (Hyperglycemia): Severe hyperglycemia, including diabetic ketoacidosis has been observed in patients treated with TRUQAP. Some cases of diabetic ketoacidosis have been reported with a fatal outcome. The risk of hyperglycemia progressing to diabetic ketoacidosis may be higher in the setting of additional co-morbidities and treatments (e.g., dehydration, malnourishment, concurrent chemotherapy/steroids, sepsis). Diabetic ketoacidosis can occur at any time during treatment with TRUQAP. In some reported cases, diabetic ketoacidosis developed in less than 10 days. Gastrointestinal (Diarrhea): Severe diarrhea associated with dehydration was observed in patients treated with TRUQAP. Advise patients to start antidiarrheal treatment at the first sign of diarrhea and to increase oral fluids if diarrhea symptoms occur while taking TRUQAP.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TRUQAP | 200 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | 02544741 |
2 · Same class — other molecules in ATC L01EX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sunitinib | AURO-SUNITINIB · EUGIA-SUNITINIB · NAT-SUNITINIB · SANDOZ SUNITINIB · +3 more | 26 | 18 | Yes |
| Lenvatinib | LENVIMA | 8 | 8 | Yes |
| Nintedanib | AURO-NINTEDANIB · EUGIA-NINTEDANIB · JAMP NINTEDANIB · OFEV | 7 | 5 | Yes |
| Avapritinib | AYVAKYT | 4 | 4 | Yes |
| Pazopanib | EUGIA-PAZOPANIB · PMS-PAZOPANIB · SANDOZ PAZOPANIB · VOTRIENT | 5 | 3 | Yes |
| Larotrectinib | VITRAKVI | 3 | 3 | Yes |
| Cabozantinib | CABOMETYX | 3 | 3 | Yes |
| Capivasertib | TRUQAP | 2 | 2 | Yes |
| Entrectinib | ROZLYTREK | 2 | 2 | Yes |
| Capmatinib | TABRECTA | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EA | Asciminib · Bosutinib · Dasatinib · Imatinib · Nilotinib · +1 more | 73 | 57 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01ED | Alectinib · Brigatinib · Ceritinib · Crizotinib · Lorlatinib | 10 | 10 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EL | Acalabrutinib · Ibrutinib · Zanubrutinib | 10 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRUQAP called?
Also recorded in Canada as: capivasertib 160 MG Oral Tablet [Truqap] (US), capivasertib 200 MG Oral Tablet [Truqap] (US), capivasertib 160 MG Oral Tablet (US), capivasertib 200 MG Oral Tablet (US), CAPIVASERTIB (US), CAPIVASERTIB (GLOBAL), CAPIVASERTIB (UK).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.